Co-silencing of WTAP and PD1 in CD8+ T cells led to a more pronounced inhibitory effect on the malignant progression of HCC cells compared to the anti-PD1 treatment alone (Figure S6A–H). Here, CD8A is linked to hepatocellular carcinoma.